Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Iovance Biotherapeutics Inc Market Cap
The Iovance Biotherapeutics Inc (IOVA) share price is expected to increase by 157.87% over the next year. This is based on calculating the average 12-month share price estimate provided by 7 stock analysts who have covered IOVA. Price targets range from $10 at the low end to $34 at the high end. The current analyst consensus for IOVA is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 7 Wall Street analysts have assigned IOVA 7 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Iovance Biotherapeutics Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on IOVA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of IOVA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Joseph Pantginis HC Wainwright & Co. | Buy | $32 | Reiterates | Aug 12, 2024 |
| Joseph Catanzaro Piper Sandler | Neutral | $10 | Downgrade | Jul 29, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $32 | Reiterates | Jun 28, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $23 | Maintains | Jun 20, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $32 | Reiterates | Jun 3, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $32 | Reiterates | May 31, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $32 | Reiterates | May 24, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $32 | Reiterates | May 10, 2024 |
| Joseph Catanzaro Piper Sandler | Overweight | $19 | Maintains | Mar 14, 2024 |
| Asthika Goonewardene Truist Securities | Buy | $26 | Maintains | Mar 7, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $32 | Reiterates | Mar 4, 2024 |
| Yanan Zhu Wells Fargo | Overweight | $25 | Maintains | Mar 1, 2024 |
| Joseph Pantginis HC Wainwright & Co. | Buy | $32 | Reiterates | Feb 29, 2024 |
| Peter Lawson Barclays | Overweight | $22 | Maintains | Feb 29, 2024 |
| Andrea Tan Goldman Sachs | Buy | $21 | Maintains | Feb 29, 2024 |
| Andrea Tan Goldman Sachs | Buy | $19 | Maintains | Feb 21, 2024 |
| Andrea Tan Goldman Sachs | Buy | $19 | Maintains | Feb 20, 2024 |
| Reni Benjamin JMP Securities | Market Outperform | $25 | Maintains | Feb 20, 2024 |
| Geulah Livshits Chardan Capital | Buy | $34 | Maintains | Feb 20, 2024 |
| Yanan Zhu Wells Fargo | Overweight | $22 | Maintains | Feb 20, 2024 |
When did it IPO
2017
Staff Count
557
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Market Cap
$2.90B
In 2023, IOVA generated $1.2M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IOVA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 26 Sep 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - Iovance Biotherapeutics is preparing to generate significant revenue and is actively working to expand its patient treatment capabilities.
Why It Matters - Iovance Biotherapeutics' plans for revenue generation and expanding patient outreach suggest potential growth, impacting its valuation and attractiveness to investors.
Mon, 16 Sep 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - Iovance Biotherapeutics is expected to take time to achieve profitability, with potential for further medicine approvals before reaching that milestone.
Why It Matters - Delayed profitability may increase financial risk for Iovance Biotherapeutics. Approval in additional markets could boost future revenue potential, influencing stock performance and investment decisions.
Fri, 06 Sep 2024
Sentiment - NEUTRAL
Source - The Motley Fool
Summary - Iovance Biotherapeutics received accelerated approval for its cell therapy, Amtagvi, and has started its rollout, signaling significant growth potential for the company.
Why It Matters - Iovance's accelerated approval for Amtagvi signals potential revenue growth and market expansion, enhancing investor confidence and prospects for stock performance.
Tue, 03 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Iovance Biotherapeutics (NASDAQ: IOVA) will have senior leadership presenting at upcoming conferences, focusing on their novel TIL therapies for cancer treatment.
Why It Matters - Iovance's participation in conferences may signal upcoming developments or insights into their TIL therapies, potentially influencing stock performance and investor sentiment.
Mon, 02 Sep 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - Iovance Biotherapeutics is experiencing its first sales growth, while CRISPR Therapeutics has begun generating significant revenue.
Why It Matters - Rising sales for Iovance Biotherapeutics and CRISPR Therapeutics indicate growing market demand, potentially boosting investor confidence and stock valuations in biotech.
Tue, 27 Aug 2024
Sentiment - POSITIVE
Source - The Motley Fool
Summary - The FDA approved Iovance Biotherapeutics' therapy Amtagvi in February. It is a complex treatment derived from immune cells in tumor biopsies.
Why It Matters - Iovance's FDA approval of Amtagvi could drive stock value higher, signaling potential revenue growth and market confidence in innovative cancer therapies.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
